



# KETAMINE & RELATED COMPOUNDS

## INTERNATIONAL CONFERENCE 2024

### Conference Program Day 1

Monday, 25<sup>th</sup> March

- 11.00** Registration
- 11.30** Anatomy of Melancholy – revision of neuroanatomy relevant to depression  
*Speaker: Laith Alexander (Kings College London)*
- 12.00** Lunch – Early Career Researchers Lunch (location TBC)
- 12.45** Welcome and Introduction  
*Speaker: Rupert McShane (University of Oxford, UK)*
- 12.55** Lateral habenula and social dominance  
*Speaker: Hailan Hu (Zhejiang University, China)*
- 13.55** Ketamine from Neurotoxicity to Neuroplasticity: A lifesaving drug that must be used with respect  
*Speaker: Jonathan Javitt (NRX pharmaceuticals, USA)*
- 14.25** R-Ketamine for Treatment Resistant Depression  
*Speaker: David Feifel (University of California, USA)*
- 14.30** Tea
- 15.00** Addiction potential of ketamine enantiomers and metabolites, and of esmethadone  
*Speaker: Mike Michaelides (National Institute on Drug Abuse, USA)*
- 15.30** Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine (the GO-MARK study)  
*Speaker: Luke Jelen (King's College London, UK)*
- 15.50** Opioid use diminishes placebo antidepressant response independently of pain in a ketamine depression trial  
*Speaker: Theresa Lii (Stanford University, USA)*
- 16.20** Short talk sessions  
IV ketamine: RWE following induction- *Speaker: Patrick Oliver (MindPeace Clinics, USA)*  
Predictors of ketamine response in 1047 patients: machine learning and RWE – *Speaker: George Wohlfold (University of Virginia, USA)*



**KETAMINE & RELATED COMPOUNDS**  
INTERNATIONAL CONFERENCE 2024

**Conference Program Day 1**

**Monday, 25<sup>th</sup> March**

**18.00** Debate at Holywell Music room followed by reception at the Weston Library

Motion: "This house believes that oral home treatment with ketamine could be widely and safely used for the treatment of resistant depression"

*Speakers For:*                    *Rupert McShane (University of Oxford, UK),*  
   *Robert Schoevers (Groningen University, The Netherland)*

*Speakers Against:*            *Alan Schatzberg (Stanford University, USA),*  
   *Zoe Cormier (Author and Journalist, UK)*

*Chair:*                                *TBC*

*The Debate is sponsored by Neurocentrx Pharma Ltd*



# KETAMINE & RELATED COMPOUNDS

## INTERNATIONAL CONFERENCE 2024

### Conference Program Day 2

**Tuesday, 26<sup>h</sup> March**

- 09.00** Pilot RCT of ketamine + Written Exposure Therapy for PTSD  
*Speaker: Adriana Feder (Icahn School of Medicine at Mount Sinai, USA)*
- 09.30** Comorbid PTSD and childhood trauma: impact on ketamine's efficacy in TRD  
*Speaker: Danica Johnson (University of Toronto, Canada)*
- 10.00** Prucalopride (5HT<sub>4</sub>a agonist) plus ketamine: additive effects on stress  
*Speaker: Christine Denny (Columbia University, USA)*
- 10.30** Coffee Break
- 11.00** Opioid-dependent mechanisms of ketamine antidepressant action  
*Speaker: Alan Schatzberg (Stanford University, USA)*
- 11.40** EEG gamma oscillations as a prognostic marker for IV ketamine in TRD  
*Speaker: Sanjay Mathew (Baylor College of Medicine, USA)*
- 12.10** Targeted ketamine delivery to the thalamus using ultrasound  
*Speaker: Raag Airan (Stanford University, USA)*
- 12.30** Lunch



**KETAMINE & RELATED COMPOUNDS**  
INTERNATIONAL CONFERENCE 2024

## Conference Program Day 2

### Tuesday, 26<sup>h</sup> March

- 13.15** Long-term safety and durable efficacy of esketamine in TRD and ESCAPE-TRD  
*Speaker: Wayne Drevets (Janssen Pharmaceutical, USA)*
- 13.45** Ketamine vs. ECT: implications for clinical practice, policy and future research  
*Speaker: Amit Anand (Harvard Medical School, USA)*
- 14.15** Machine learning to predict response to ECT vs (es)ketamine  
*Speaker: Michael Henry (Harvard Medical School, USA)*
- 14.35** Short talk sessions  
IV esketamine in TRD - RWE following induction - *Speaker: Tiago Gill (Centro de Cetamina, Brazil)*
- 14.45** Tea
- 15.15** Implementation of emerging psychedelics: models of support and interventional psychiatry  
*Speaker: Steve Levine (COMPASS Pharmaceuticals, USA)*
- 15.45** Title TBC  
*Speaker: Robert Schoevers (University of Groningen, The Netherlands)*
- 16.15** Mesmer, Cardiac Surgery, and Ketamine: Appreciating the Power of Contextual Effects  
*Speaker: Gerard Sanacora (Yale University, USA)*
- 
- 18.45** Pre-dinner drinks – Fellows Garden, Exeter college
- 19.30** Conference Dinner – Exeter College Dining Hall



# KETAMINE & RELATED COMPOUNDS

## INTERNATIONAL CONFERENCE 2024

### Conference Program Day 3

#### Wednesday, 27<sup>h</sup> March

- 09.00** Mouse model of anorexia: effects of ketamine in adults and adolescents  
*Speaker: Chiye Aoki (New York University, USA)*
- 09.30** RCT of dextromethorphan vs psilocybin: effects in healthy volunteers with history of hallucinogen use  
*Speaker: David Mathai (Johns Hopkins, USA)*
- 10.00** Psilocybin and ketamine: two side of the same coin?  
*Speaker: David Nutt (Imperial College London, UK)*
- 10.30** Coffee Break
- 11.00** RCT of ketamine for OCD  
*Speaker: Peter van Roessel (Stanford University, USA)*
- 11.30** Psychological mechanisms of change in ketamine treatment: findings of two mechanistic studies  
*Speaker: Celia Morgan (University of Exeter, UK)*
- 12.00** Title TBC  
*Speaker: Julia Aepfelbacher (University of Pittsburgh, USA)*
- 12.30** Lunch



# KETAMINE & RELATED COMPOUNDS

## INTERNATIONAL CONFERENCE 2024

### Conference Program Day 2

#### Wednesday, 27<sup>h</sup> March

- 13.15** Dose finding study of prolonged release oral ketamine formulation  
*Speaker: Hans Eriksson (Ketabon, USA)*
- 13.35** Keticap immediate release, abuse deterrent: Phase 1 data  
*Speakers: Daniel Silman (Kings College, UK)*
- 13.55** Pilot RCT of ethosuximide in TRD: efficacy and safety  
*Speakers: Shaohua Hu (Zhejiang University, China)*
- 14.15** Short talk sessions  
EEG dissociation - *Speaker: Marco Fabus (University of Oxford, UK)*  
Influence of ketamine on the effect of expectations on perceptual and emotional learning  
- *Speaker: Lilian Weber (University of Oxford, UK)*  
Title TBD - *Speaker: TBD*
- 14.45** Tea
- 15.45** RCT of ketamine for depression in Parkinson's disease  
*Speaker: Sophie Holmes (Yale University)*
- 16.05** Bladder symptoms: prospective long-term data in 295 patients - *Speaker: Rupert McShane (University of Oxford, UK)*
- 16.25** Leveraging the diverse properties of ketamine to address psychiatric challenges  
*Speaker: Elias Dawkar (Columbia University, USA)*
- 16.55** Closing remarks  
*Speaker: Rupert McShane, University of Oxford, UK*



**KETAMINE & RELATED COMPOUNDS**  
INTERNATIONAL CONFERENCE 2024

We wish to thank our sponsors:



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

**neurocentrx**

**KETABON** 

**NRX**